An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer

Study Overview

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer.

Study Description

The purpose of this study is to evaluate the safety of Gedatolisib plus PTK7-ADC in patients with metastatic triple-negative or estrogen poor breast cancer as assessed by NCI CTC v4.0 criteria.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1704239900 (IUSCC-0613)
  • Research Study Identifier: TX7919
  • Principal Investigator: Kathy Miller, MD

Recruitment Status

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.